The trading price of Virax Biolabs Group Ltd (NASDAQ:VRAX) closed higher on current market day and closing at $4.89, 6.07% higher than its previous close.
Traders who pay close attention to intraday price movement should know that it fluctuated between $4.32 and $4.92. In examining the 52-week price action we see that the stock hit a 52-week high of $9.00 and a 52-week low of $0.60. Over the past month, the stock has gained 285.04% in value.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Virax Biolabs Group Ltd, whose market valuation is $11.54 million at the time of this writing, is expected to release its quarterly earnings report in September. Investors’ optimism about the company’s current quarter earnings report is understandable.
On the technical side, indicators suggest VRAX has a 100% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Buy, while an average of long term indicators suggests that the stock is currently 100% Buy.
A quick review shows that VRAX’s price is currently 101.88% off the SMA20 and 182.71% off the SMA50. The RSI metric on the 14-day chart is currently showing 62.80, and weekly volatility stands at 38.46%. When measured over the past 30 days, the indicator reaches 32.94%. Virax Biolabs Group Ltd (NASDAQ:VRAX)’s beta value is currently sitting at 1.75, while the Average True Range indicator is currently displaying 1.03.
To see how Virax Biolabs Group Ltd stock has been performing in comparison to its peers in the industry, here are the numbers: VRAX stock’s performance was 6.07% in the latest trading, and 29.83% in the past year.
An evaluation of the daily trading volume of Virax Biolabs Group Ltd (NASDAQ:VRAX) indicates that the 3-month average is 4.38 million. However, this figure has increased over the past 10 days to an average of 18.35.
Currently, records show that 2.57 million of the company’s shares remain outstanding. The insiders hold 12.19% of outstanding shares, whereas institutions hold 3.00%. The stats also highlight that short interest as of 2024-07-31, stood at 18866.0 shares, resulting in a short ratio of 0.17 at that time. From this, we can conclude that short interest is 103.00 of the company’s total outstanding shares. It is noteworthy that short shares in July were down slightly from the previous month’s figure, which was 65132.0. However, since the stock’s price has seen 234.93% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.
